The annual number of administrations and annual consumption (in IU) per patient associated with prophylactic treatment with recombinant coagulation factor VIII (rVIIIF) available in Spain in patients with severe haemophilia A (≥12 years) was estimated and compared. The results determined that an increased use of damoctocog alfa pegol in prophylaxis would result in a significant reduction in the annual number of administrations and annual consumption of IU, and could generate a more predictable annual budgetary impact for Spanish hospitals.
